Purification, biochemistry and functional characterization of a new L-amino acid oxidase from Lachesis muta venom.

As peçonhas de serpentes contêm uma mistura complexa de substâncias farmacologicamente ativas, como metaloproteases, fosfolipases A2, serino-proteases, L-aminoácido oxidase (LAAO), além de outros importantes compostos sem ação enzimática. LAAOs são flavoproteínas que catalisam a desaminação oxidativa de L-aminoácidos e produzem o -cetoácido correspondente, com a concomitante liberação de amônia e peróxido de hidrogênio. A peçonha de Lachesis muta (L. muta) contém L-aminoácido oxidase, a qual pode contribuir com o envenenamento. Portanto, o objetivo deste trabalho é a purificação da L-amino acido oxidase de peçonha de Lachesis muta (LmLAAO) e a sua caracterização bioquímica, estrutural e funcional. Para isso, foram desenvolvidos dois protocolos distintos de purificação, os quais forneceram LmLAAO com grande pureza. No primeiro protocolo, 20 mg de peçonha bruta de L. muta foram submetidos a uma gel filtração em Sephacryl S100®. Das dez frações obtidas, a primeira fração apresentou atividade L-aminoácido oxidase e foi submetida a mais um passo cromatográfico em Mono Q®. A homogeneidade da fração com atividade L-aminoácido oxidase após a troca iônica foi comprovada por presença de banda única com 60,2 kDa em SDS-PAGE. O segundo protocolo de purificação foi uma sequência de três passos cromatográficos, na qual 200 mg de peçonha bruta de L. muta foram submetidos a gel filtração em Sephacryl S200®, seguido por interação hidrofóbica em Phenyl Sepharose® e Affi- gel Blue Gel®. Da mesma forma, a pureza da enzima obtida depois desses passos cromatográficos foi comprovada por presença de banda única com 64 kDa em SDS-PAGE. Em ambos os protocolos de purificação, LmLAAO manteve sua atividade enzimática. A massa molar de LmLAAO foi determinada por espectrometria de massas (MALDI-TOF) e apresentou valor de 60,85 kDa. Além disso, foi determinado o valor do ponto isoelétrico da LmLAAO como 5,1. A LmLAAO mostrou preferência catalítica por aminoácidos hidrofóbicos (L-Metionina L-Leucina e L-Fenilalanina) e apresentou perda de atividade catalítica quando submetida à altos valores de pH ou de temperatura. Os parâmetros cinéticos foram determinados e a constante de Michaelis-Menten para o substrato L-Leucina foi de 0,9737 mmol/L e a velocidade máxima de reação foi de 0,06345 mol peróxido de hidrogênio/min. A sequência N-terminal dos 40 primeiros resíduos da LmLAAO purificada foi determinada por degração de Edman e a sua estrutura primária completa foi deduzida da sequência do cDNA obtido da glândula de peçonha. Verificou-se uma grande identidade entre as sequências em aminoácidos da LAAO de L. muta e as de outros viperídeos. A estrutura da LmLAAO foi resolvida por substituição molecular usando as coordenadas atômicas da LAAO de Agkistrodon halys pallas (PDB 1REO). As atividades farmacológicas da LmLAAO foram determinadas in vivo e in vitro. A injeção da enzima (10 µg) não induziu edema de pata em camundongos, nem hemorragia (50 µg) e nem toxicidade sistêmica (100 µg). No entanto, provocou uma leve mionecrose (100 µg) e edema em músculo quadríceps de camundongo, aumentando a creatina quinase plasmática. In vitro, foram testadas as atividades citotóxicas da LmLAAO em células de carcinoma. Os dados obtidos mostram IC50 de 22,70 µg/mL, para linhagem AGS (carcinoma de estômago), e IC50 de 1,41 µg/mL linhagem MCF-7 (carcinoma de mama). Para a atividade antiparasitária, foi determinada uma IC50 de 2,22 µg/mL para a forma promastigota de Leishmania brasiliensis. No entanto, a LmLAAO (32 µg/mL) não apresentou toxicidade relevante para a forma tripomastigota de Tripanosoma cruzi. Concluindo, este trabalho descreve o isolamento e a caracterização estrutural e funtional de uma nova LAAO da peçonha de L. muta. A enzima mostrou efeitos antitumorais e leishmanicida, sem toxicidade sistêmica relevante, mas apresentou significativa ação edematogênica e miotóxica local. Este estudo é relevante não apenas por contribuir para uma melhor compreensão do papel da LAAO no envenenamento, mas também por demonstrar seu potencial biotecnológico como agente terapêutico.Snake venoms comprise a complex mixture of pharmacologically active substances, such as metalloproteases, phospholipase A2, serine proteases and L-amino acid oxidases (LAAOs) other compounds showing no enzymatic activity. LAAOs are flavoproteins catalyzing the oxidative deamination of L-amino acids to produce the corresponding -keto acid with the concomitant release of ammonia and hydrogen peroxide. Lachesis muta (L. muta) venom contains L-amino acid oxidase which may contribute to the envenomation. The aim of this study is the purification of an L-amino acid oxidase from Lachesis muta venom (LmLAAO) and its structural and functional characterization. For that, two purification protocols were performed and both provided highly pure LmLAAO. In the first protocol, 20 mg of crude venom of L. muta were submitted to a gel filtration on Sephacryl S100® and yielded ten fractions, whose were tested for L-amino acid oxidase activity. The first fraction showed L-amino acid oxidase activity and it was submitted to a further chromatographic step on Mono Q®. The homogeneity of the fraction showing L-amino acid oxidase activity after ion exchange was confirmed by the presence of a single band corresponding to 60.2 kDa by SDS-PAGE. The second purification protocol was a sequence of three chromatographic steps, where 200 mg of crude L. muta venom were submitted to gel filtration on Sephacryl S200, followed by hydrophobic interaction on Phenyl Sepharose® and Affi-gel-Blue Gel. For the second protocol, the purity of LmLAAO was confirmed by the presence of a single band with 64 kDa as determined by SDS-PAGE. In both purification protocols LmLAAO kept its enzymatic activity. The molar mass of LmLAAO was determined by mass spectrometry (MALDI-TOF) and showed a value of 60.85 kDa. Moreover, the isoelectric point was 5.1. In addition, LmLAAO showed a catalytic preference for hydrophobic amino acids (L-methionine, L-leucina and L-phenylalanine) and lost its catalytic activity when subjected to high pH or temperature. The kinetic parameters for LAAO were determined and the Michaelis-Menten constant for the substrate L-leucine was 0.9737 mmol/L, and the maximum reaction velocity was 0.06345µmol hydrogen peroxide/min. Furthermore, the sequence of the first forty residues was determined by Edman degradation and the complete sequence of LmLAAO was resolved by cloning cDNA obtained from the venom glands. The amino acid sequence of LmLAAO showed a great identity with sequences of LAAOs from other viper snakes. The LmLAAO structure was solved by molecular replacement using the the atomic coordinates of the LAAO from Agkistrodon halys pallas (PDB 1REO). In addiction, LmLAAO pharmacological activities were determined in vivo and in vitro. Thus, LmLAAO (10 µg) did not induce paw edema in mice, neither hemorrhage (50 µg) nor systemic toxicity (100 µg). However, it caused a mild myonecrosis (100 µg) and edema in the quadriceps muscles of mice, increasing plasma creatine kinase. In vitro activities of LmLAAO in carcinoma cells was assayed. The IC50 of LmLAAO on AGS cell line (stomach cancer) was 22.70 µg / mL, and the IC50 of LmLAAO on MCF-7 cell line (breast carcinoma) was 1.41 µg/mL. Moreover, antiparasitic activity of LmLAAO was determined on promastigote of Leishmania brasiliensis and an IC50 of 2.22 µg/mL was found, whereas on trypomastigote form Trypanosoma cruzi LmLAAO showed no toxicity at doses of 32 µg/mL. In conclusion, this work reports the isolation and the structural and funtional characterization of a new LAAO from L. muta snake venom. The enzyme showed antitumoral and leishmanicidal effects, without relevant systemic toxicity, but presented a significant local edema inducing and myotoxic action. This study is relevant not only for contributing to a better understanding of LAAO role in envenomation, but also for demonstrating its biotechnological potential as a therapeutic agent

Purification and enzymatic characterization of a novel metalloprotease from Lachesis muta rhombeata snake venom

Abstract Background Lachesis muta rhombeata (Lmr) is the largest venomous snake in Latin America and its venom contains mainly enzymatic components, such as serine and metalloproteases, L-amino acid oxidase and phospholipases A2. Metalloproteases comprise a large group of zinc-dependent proteases that cleave basement membrane components such as fibronectin, laminin and collagen type IV. These enzymes are responsible for local and systemic changes, including haemorrhage, myonecrosis and inflammation. This study aimed the isolation and enzymatic characterization of the first metalloprotease (Lmr-MP) from Lmr venom (LmrV). Methods and results Lmr-MP was purified through two chromatographic steps and submitted to enzymatic characterization. It showed proteolytic activity on azocasein with maximum activity at pH 7.0–9.0. It was inhibited by EDTA (a metal chelator that removes zinc, which is essential for enzymatic activity) and no effect was observed with PMSF, iodoacetic acid or pepstatin (inhibitors of serine, cysteine and aspartyl proteases, respectively). Ca2+, Mg2+ and Ba2+ ions increased its activity, while Al3+, Cu2+, Ni2+ and Zn2+ inhibited it. Additionally, ZnCl2 showed a dose dependent inhibition of the enzyme. Lmr-MP activity was also evaluated upon chromogenic substrates for plasma kallikrein (S-2302), plasmin and streptokinase-activated plasminogen (S-2251) and Factor Xa (S-2222) showing the highest activity on S-2302. The activity in different solutions (5 mM or 50 mM ammonium bicarbonate, pH 7.8; 0.1% trifluoroacetic acid + 50% acetonitrile; phosphate buffer saline, pH 7.4; 50 mM sodium acetate, pH 4.0 or ammonium acetate pH 4.5) was also evaluated and the results showed that its activity was abolished at acidic pHs. Its molecular mass (22,858 Da) was determined by MALDI-TOF and about 90% of its primary structure was verified by high-resolution mass spectrometry using HCD and ETD fragmentations and database search against the sequence of closely related species. It is a novel enzyme which shared high identity with other snake venom metalloproteases (svMPs) belonging to the P-I group. Conclusion The purification procedure achieved a novel pure highly active metalloprotease from LmrV. This new molecule can help to understand the metalloproteases mechanisms of action, the Lachesis envenoming, as well as to open new perspectives for its use as therapeutic tools

Isolation and biochemical, functional and structural characterization of a novel L-amino acid oxidase from Lachesis muta snake venom

The aim of this study was the isolation of the LAAO from Lachesis muta venom (LmLAAO) and its biochemical, functional and structural characterization. Two different purification protocols were developed and both provided highly homogeneous and active LmLAAO. It is a homodimeric enzyme with molar mass around 120 kDa under non-reducing conditions, 60 kDa under reducing conditions in SDS-PAGE and 60852 Da by mass spectrometry. Forty amino acid residues were directly sequenced from LmLAAO and its complete cDNA was identified and characterized from an Expressed Sequence Tags data bank obtained from a venom gland. A model based on sequence homology was manually built in order to predict its three-dimensional structure. LmLAAO showed a catalytic preference for hydrophobic amino acids (Km of 0.97 mmol/L with Leu). A mild myonecrosis was observed histologically in mice after injection of 100 μg of LmLAAO and confirmed by a 15-fold increase in CK activity. LmLAAO induced cytotoxicity on AGS cell line (gastric adenocarcinoma, IC50: 22.7 μg/mL) and on MCF-7 cell line (breast adenocarcinoma, IC50:1.41 μg/mL). It presents antiparasitic activity on Leishmania brasiliensis (IC50: 2.22 μg/mL), but Trypanosoma cruzi was resistant to LmLAAO. In conclusion, LmLAAO showed low systemic toxicity but important in vitro pharmacological actions.Fundação de Amparo à Pesquisa do Estado de São Paulo/[2005/54855-0]/FAPESP/BrasilInstituto Nacional de Ciência e Tecnologia de Toxinas//INCTTox/BrasilConselho Nacional de Desenvolvimento Científico e Tecnológico/[479873/2009-7]/CNPq/BrasilConselho Nacional de Desenvolvimento Científico e Tecnológico/[142711/2007-1]/CNPq/BrasilUCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias de la Salud::Instituto Clodomiro Picado (ICP